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West Nile virus (WNV) can lead to fatal diseases in raptor species. Unfortunately, there is no vaccine which has been
designed specifically for use in breeding stocks of falcons. Therefore the immunogenicity and protective capacity of
two commercially available WNV vaccines, both approved for use in horses, were evaluated in large falcons. One
vaccine contained adjuvanted inactivated WNV lineage 1 immunogens, while the second represented a canarypox
recombinant live virus vector vaccine. The efficacy of different vaccination regimes for these two vaccines was
assessed serologically and by challenging the falcons with a WNV strain of homologous lineage 1. Our studies show
that the recombinant vaccine conveys a slightly better protection than the inactivated vaccine, but moderate
(recombinant vaccine) or weak (inactivated vaccine) side effects were observed at the injection sites. Using the
recommended 2-dose regimen, both vaccines elicited only sub-optimal antibody responses and gave only partial
protection following WNV challenge. Better results were obtained for both vaccines after a third dose, i.e. alleviation
of clinical signs, absence of fatalities and reduction of virus shedding and viraemia. Therefore the consequences of
WNV infections in falcons can be clearly alleviated by vaccination, especially if the amended triple administration
scheme is used, although side effects at the vaccination site must be accepted.Introduction
West Nile virus (WNV) is a Flavivirus belonging to the
family Flaviviridae and is encoded by a positive sense,
single stranded RNA genome. The virus is distributed
worldwide [1]. Whereas until the mid 1990s WNV dis-
ease was perceived as sporadic and mild in humans and
horses, larger scale epidemics were discovered in subse-
quent years [2]. In birds WNV was first isolated in Egypt
in 1953 [3]. However major outbreaks amongst domestic
birds occurred in Israel in 1997 and thereafter. Besides
also wild birds were affected [4,5]. In 1999, WNV was
introduced to New York City and spread from there to
almost the whole American continent. WNV is transmit-
ted between birds by mosquitoes, especially Culex spe-
cies, in an enzootic transmission cycle [6]. Passeriformes
and also raptor species are highly susceptible, develop
high virus titers and can succumb to the disease [7].* Correspondence: martin.groschup@fli.bund.de
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article, unless otherwise stated.Natural disease producing WNV lineage 1 infections
have been described in falcon species including gyrfalcon
(Falco rusticolus), peregrine falcon (F. peregrinus), prairie fal-
con (F. mexicanus), merlin (F. columbarius) and American
kestrel (F. sparverius) [8,9].
Fatal WNV lineage 2 infection has been reported during
the epidemic in Austria in one gyrfalcon [10]. The sus-
ceptibility of various raptor species has been confirmed
in experimental WNV infection studies. Large falcons
are susceptible to WNV [11] and developed subclinical
to fatal disease as competent amplifying hosts after ex-
perimental infection with WNV [12]. Subunit vaccines,
inactivated vaccines and DNA vaccines against WNV in-
fections were used with variable success in birds. Vaccine
efficacy in these studies was determined by experimental
WNV challenge of the birds [13-21] or by determination
of neutralizing antibody response [22-24].
Birds of prey, especially falcons, are bred in captivity
for species conservation and commercial purposes. As
WNV infections in these breeding flocks may cause sub-
stantial losses, the availability of an efficacious vaccine
with minimal side effects is desirable. However, only veryntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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After vaccination with a DNA vaccine, California condors
developed neutralizing antibody responses but no challenge
experiment was carried out [22]. Such a vaccination/
challenge study in raptors has only been done once
using a DNA vaccine in red-tailed hawk [19]. Although
the seroconversion rate following a two dose regimen
was low (only 3 of 14 hawks developed a detectable yet low
antibody titre) and viremia was significantly reduced, virus
shedding was not affected. However, none of the WNV
infected hawks in the control group showed any clinical
signs, which certainly limits the interpretation of this study.
In the study presented herein, two commercially avail-
able WNV vaccines for equines were evaluated, namely
Duvaxyn® WNV, Fort Dodge (Fort Dodge Animal Health
Limited, Hedge End, Southhampton, England; in the EU
now Equip® WNV, Zoetis Belgium SA, Louvain-la-Neuve,
Belgium; in the US WEST NILE-INNOVATOR®, Zoetis
Inc., Florham Park, NJ, USA) and RECOMBITEK®-
Equine rWNV vaccine, Merial Limited, Duluth, USA
(now approved in the EU as Proteq West Nile, Merial,
Lyon, France). Duvaxyn® was used before in avian species
[23,25], including raptors (peregrine falcon, American
kestrel and red-tailed hawk). Three immunizations
with this vaccine resulted in low antibody titers in 60%
of the animals, but again challenge experiments were not
conducted [26]. In another study red-tailed hawks failed
to develop detectable antibodies after immunization with
this vaccine [27]. RECOMBITEK® was previously tested
in Western scrub-jays (Aphelocoma californica) and
provided partial protection, but also caused consider-
able side effects [20]. The present study first estimates
the efficacy of these two WNV vaccines in large falcons
confirmed by live virus challenge.
Materials and methods
Animals
The animals used in this study were 29 captive-bred
mature (> 6 months old) gyrfalcons and hybrid falcons
(F. rusticolus × F. cherrug and F. rusticolus × F. peregrinus).
Birds were clinically healthy (clinical examination and
endoscopy) and were dewormed prior to the vaccination
trial. Susceptibility to WNV infection was determined by
serologic assays that were negative for WNV and a closely
related (cross-reactive) European flavivirus, Usutu virus.
Vaccines/vaccination
The first vaccine used in this study was a commercially
available inactivated WNV vaccine approved in the EU
for use in horses, named Duvaxyn® WNV, Fort Dodge
(in the EU now Equip® WNV, Zoetis; in the US WEST
NILE-INNOVATOR®, Zoetis). It contains the formalin
inactivated whole WNV VM-2, which is a North American
isolate belonging to lineage 1 [28]. The second vaccine usedin this study was a recombinant live vaccine, also approved
for use in horses (RECOMBITEK®- Equine rWNV vaccine,
Merial, US, approved in the EU as Proteq West Nile). It
consists of recombinant live canarypox virus ALVAC which
co-expresses WNV prM and E proteins of a NY’99 isolate
(lineage 1). During the vaccination phase with Duvaxyn®
birds were held in a hexagonal 125 m2 sized and 6 m
high aviary in a breeding centre for falcons. Animals
vaccinated with the Recombitek® vaccine were kept in an
aviary at FLI, Isle of Riems, under safety level 2 conditions
(as this genetically engineered vaccine was not approved
in Europe at the time). Falcons were fed commercial one-
day-old chicks and provided with water ad libitum.
Falcon groups 1 (n = 5, Duvaxyn® WNV) and 3 (n = 5,
RECOMBITEK® West Nile) were vaccinated using a full
dose (1 mL) intramuscular (doses split evenly and inocu-
lated into both sides of pectoral muscles). Booster injections
were given four weeks post vaccination (wpv) and the ani-
mals were challenged eight weeks after the first vaccination
(for vaccine groups see Table 1). Groups 2 (n = 5, Duvaxyn®
WNV) and 4 (n = 5, RECOMBITEK® West Nile) received
two booster injections 3 and 6 wpv, and were challenged
eight weeks after the first vaccination. Group 5 (n = 8)
served as non-vaccinated control group. These birds were
subdivided and 2 falcons per infection group were handled
and housed together with the vaccinated individuals. One
bird served as non-vaccinated, non-challenged control
referred to as group 6 (n = 1) and was housed together
with animals of group 3. During the course of vaccination
the health status of the falcons was assessed daily, and every
week a clinical examination was conducted as described
later with additional palpation of the vent, auscultation
of heart and lungs, inspection of nares, pharynx, mucous
membranes, feet, skin and muscles at the vaccination sites.
Blood samples as well as swabs from oropharynx and clo-
aca were taken weekly. These samples were used for WNV
antibody determination by ELISA along with VNT and for
WNV as well as recombinant vaccine genome detection,
respectively. During these procedures birds were anesthe-
tized with isoflurane inhalation anaesthesia.
Animal vaccination and challenge experiments described
in this manuscript were approved by the competent author-
ity of the Federal State of Mecklenburg-Western Pomerania,
Germany (reference number 7221.3–1.1.-056/10) on
the basis of national and European legislation, namely EU
council directive 86/609/EEC for the protection of animals
used for experiments.
Nested PCR for detecting recombinant vaccine shedding
Oropharyngeal and cloacal swab samples were placed in
sterile polypropylene tubes filled with 2 mL of minimal
essential medium (MEM) supplemented with antimicrobial
drugs and stored at −70 °C for further examinations. Viral
DNA was extracted from swab sample supernatants using
Table 1 Viral load of organs in tissue culture infectious dose 50 (TCID50) and genome copies













Group 1 F14 21 0/0 0/0 0/0 0/0 0/0 0/0
Inactivated F15 19 0/4.6 0/0.4 0/0.9 0/0 0/0.1 0/0
Boost: 4 wpv F16 20 0/24.8 0/3.8 0/143 0/0 0/0 0/1.8
Challenge: 8 wpv
F17 9 18.7/2530 0/3441 0.2/4479 0/6583 0/290 1164/38565819
F18 21 0/4.7 0/0.9 0/223 0/0 0/0.1 0/2.6
Group 2 F37 19 0/0 0/0 0/0 0/0 0/0 0/0
Inactivated F38 20 0/0 0/0 0/0 0/0 0/0.2 0/0
Boost: 3 + 6 wpv F40 19 0/0.6 0/0 0/0 0/0 0/0 0/0
Challenge: 8 wpv F41 20 0/0 0/1.4 0/0 0/0 0/0 0/0
Group 3 F19 20 0/0 0/0 0/0.6 0/0 0/0 0/0
Recombinant F20 19 0/0 0/0 0/0 0/0 0/0 0/0
Boost: 4 wpv F21 21 50.8/4337 0/0 0/141 0/0 0/0 0/0
Challenge: 8 wpv
F22 21 0/0 0/0 0/0 0/0 0/0 0/0
F23 20 0/0 0/0 0/0 0/0 0/0 0/0
Group 4 F44 20 0/6 0/0.1 0/0 0/0 0/0 0/0
Recombinant F45 19 0/0 0/0 0/0 0/0 0/0 0/0
Boost: 3 + 6 wpv F47 21 0/0 0/0 0/0 0/0 0/0 0/0
Challenge: 8 wpv F48 19 0/0 0/0 0/0 0/0 0/0 0/0
Group 5 F13 19 0.6/112 0/17.9 0/3.9 0/0.1 0/0.3 0/4.6
Control F24 20 0/32.1 0/0 0/822 0/0 0/0 0/4.7
No vaccination
F27 14 8.7/132202 0/42 0/403 0/36.9 0/16.7 37.9/7794
F36 20 0/23.6 0/0 0/2 0/0 0/0 0/0
F42 5 46.9/515 175/318323 76.2/14400 601/5456 94.4/32119 19/6563
F43 20 0.4/38.2 0/11.4 0/1.5 0/0 0/0.1 0/0.1
F51 8 738/2668 10.7/8631 2896/82091 7558/63844 3023/402895 4380/295311
F55 3 0/12.3 3.3/2376 3.9/796 13.2/465 0.9/249 5.4/380
Group 6
F63 21 0/0 0/0 0/0 0/0 0/0 0/0
Env. Control
Abbreviations: copies = genome copies; dpi = days post infection, Env. = environmental, wpv = weeks post vaccination.
Values are given per mg tissue. High TCID50 were found in birds that died after infection, whereas virus was scarce or absent in birds that survived the whole
three-week challenge period. Sensitivity of qRT-PCR was generally higher than virus titration in cell culture. Statistical analysis of viral load was performed for brain,
spleen, kidney and heart. There is a statistically significant difference to group 5 in brain, kidney and heart of group 2; spleen, kidney and heart of group 3 and in
brain, kidney and heart of group 4.
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according to the manufacturer’s instructions. The PCR
used the following primers (fw CTCGTTAATTAATTA
GAGCTTC and rev CAATGCATAGGTTCTTTCCAGC)
binding in the ALVAC vector and in the WNV prM gene,
respectively [29]. PCR was performed using the Fermentas
Dream TaqTM DNA Polymerase (Thermo Fisher Scientific
Inc., Waltham, MA, USA) and the following temperature
profile: 95 °C for 3 min and 40 × 95 °C for 30 s, 47.8 °C for
30 s, 72 °C for 1 min and then 72 °C for 15 min. The nested
PCR used the internal primers (nfw CAAAGGTTCTTGAG
GGTTGTG and nrev GTTGGAATCGTGATGACATCTG)and the following temperature profile: 95 °C for 3 min
and the 40 × 95 °C for 30 s, 52.9 °C for 30 s, 72 °C for
1 min and 72 °C for 15 min. The commercial vaccine
virus RECOMBITEK® served as positive control. Spike
experiments showed no inhibitory effects of falcon
oropharyngeal and cloacal swabs, and serial dilution series
revealed a sensitivity of detection of ≈ 170 copies/PCR reac-
tion (based on the canarypox genome size).
WNV challenge of the falcons
WNV lineage 1 NY99 was used for challenge experiments
(GenBank accession no. AF196835, virus identity verified
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propagated on Vero E6 cells (FLI, Greifswald, Germany)
and virus titers were determined. Challenge virus doses
diluted in MEM contained 106 Tissue Culture Infection
Dose 50 (TCID50) in 1 mL. All WNV infection studies were
carried out under biosafety level 3 conditions. Two vacci-
nated groups (group 1 + 3 or group 2 + 4, respectively), two
non-vaccinated birds of group 5 and one non-vaccinated,
non challenge control bird (group 6) were kept together
in one room.
Animals were caged separately and fed commercial one-
day-old chicks ad libitum (maximum eight chicks per day).
Infections were carried out subcutaneously in the left in-
guinal region under isoflurane inhalation anaesthesia [30].
Following infection all falcons were examined daily
for the following criteria, which were summed up using
a clinical score system: general condition, posture, plumage,
behaviour, excrements, neurological status, hydration status,
respiration and food uptake. A clinical score was deter-
mined by adding 0 to 3 points for deviation in each criterion
from normal state (−, +, ++, +++) to a total sum. Four clin-
ical score classes were defined as follows. Clinical score of
0 = healthy (0 to 0.5 deviation points), 1 =mildly affected (1
to 4.5 deviation points), 2 =moderately affected (5 to 10.5
deviation points), 3 = severely affected (11 to 24 deviation
points) and 4 = death. In parallel to sampling, temperature,
body weight, body condition score and hydration status were
measured under isoflurane inhalation anaesthesia. Sampling
included blood samples, oropharyngeal and cloacal swabs
and was performed on 0, 3, 6, 8 (only swabs), 10, 12 (only
swabs), 14 and 19/20/21 days post infection (dpi) (or earlier
in case of euthanasia). Blood was diluted in bovine albumin-
1 (BA-1) diluent [31] immediately after sampling and stored
at −70 °C until further analysis. Swabs were transferred to
2 mL MEM supplemented with antibiotics (1 g/L enrofloxa-
cin, 0.5 g/L spectinomycin, 0.25 g/L lincomycin and 0.05 g/L
gentamycin) and shaken for 30 min at room temperature.
Dead animals were examined pathologically and organ sam-
ples (brain, spleen, kidney, lung, liver, and heart) were fixed
in formalin or stored in supplemented MEM at −70 °C.
Virus isolation
Organ samples in supplemented MEM were homogenized
in a tissue lyser bead mill (Qiagen). Serial dilutions of
organ-homogenate supernatants and of BA-1 blood di-
lutions were used to inoculate Vero cells. After seven
days of incubation, cells were formalin-fixed, stained
with crystal violet and virus titers calculated using the
Spearman and Kaerber method [32].
Serological assays
After centrifugation, sera were assayed by ID Screen©
WN competition ELISA (IDVet, Grabels, France) following
the manufacturer’s instructions.Neutralizing WNV antibody titers were determined
by VNT on Vero cells as published previously [33] using
1:10, 1:20, 1:40 etc. dilutions (in MEM) and homologous
challenge virus (100 TCID50 of WNV lineage 1 NY99,
GenBank accession no. AF196835). Assays were read
after seven days after formalin-fixation and crystal violet
staining of the cell monolayers. Cytopathogenic effects
were measured and neutralizing titres were calculated using
the Behrens-Kaerber method [34]. Neutralization test
for Usutu virus (USUV) was performed under the same
conditions using USUV strain Vienna 2001 (GenBank
accession no. AY453411.1).
Quantitative real-time RT-PCR (qRT-PCR)
Viral RNA was isolated from swab samples and organ
homogenate supernatants using the QIAamp® Viral RNA
Kit (Qiagen). Viral RNA of blood in BA-1 medium was
extracted using the RNeasy® Mini Kit (Qiagen) follow-
ing the manufacturer’s instructions including a TRIzol®
(Life Technologies, Carlsbad, CA, USA) chloroform step.
An internal control RNA (IC RNA) containing 2 × 105
copies/μL was extracted together with all samples, which
were then stored at −70 °C.
Two previously published qRT-PCRs which target either
the 5′NTR-region or the NS2A-region were used [35].
Viral loads were determined based on cycle threshold (CT)
values and in case of organ samples quantified as copies/μL
RNA using an external calibrator control [35].
Histopathology/Immunohistochemistry (IHC)
Tissue samples were fixed in neutral buffered formalin
(4%), embedded in paraffin, 3 μm sections were cut and
stained with haematoxylin/eosin (HE). For IHC 3 μm
sections were cut, deparaffinised and rehydrated. As primary
antibody mab 15R4 (kindly provided by Petra Emmerich,
Bernhard-Nocht Institute, Hamburg, Germany) was used at
a dilution of 1:20 in goat serum (FLI). To verify inconclusive
results mab 3B2 (kindly provided by Davide Lelli, Istituto
Zooprofilattico Sperimentale della Lombardia e dell’Emilia
Romagna, Brescia, Italy) was used at a dilution of 1:80 in
goat serum. Endogenous peroxidase was blocked by 3%
H2O2/methanol incubation and antigen was retrieved by
Proteinase K digestion (15 min at 37 °C with 4 μg/mL).
On sections incubated with mab 3B2 high-temperature
citrate buffer (pH 6.0, microwave for 10 min) was addition-
ally applied. As secondary antibody Mouse Envision HRP
(Dako Diagnostics, Dako Deutschland GmbH, Hamburg,
Germany) and as substrate diaminobenzidine were used.
Brains, hearts, spleens, kidneys and the virus injection sites
were evaluated. Depending on the proportion of positive tis-
sue in the slide, the organ was scored from 0 to 3 (0 = no
positive tissue = negative, 1 = < 1% positive tissue =mildly
affected, 2 = ≥ 1% and < 5% positive tissue = moderately
affected, 3 = ≥ 5% positive tissue = severely affected).
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All statistical tests were conducted using R software [36].
Always one group was tested independently against the
control group. P-values below α-levels of 0.05 were consid-
ered statistically significant. After addition of clinical scores
of all days for each falcon they were compared using one-
sided Wilcoxon rank sum test with continuity correction.
For 19, 20 and 21 dpi the arithmetic means of these 3 days
were used. The same applies to mean duration time of ill-
ness. Duration of illness was defined as the sum of all days
one falcon had a clinical score of 1 to 3. A clinical score of
4 was not included in duration of disease. Variance analyses
for oral and cloacal shedding levels and viraemia levels were
conducted by ANOVA over all sampled days. The duration
of shedding and viraemia was evaluated by the one-sided
Wilcoxon rank sum test with continuity correction by using
a cut off Ct value of 35.0 as negative in qRT-PCR. For ana-
lysis of viral load in organs (brain, spleen, kidney, heart) the
values of all surviving falcons were evaluated by one-sided
Wilcoxon rank sum test with continuity correction.
Results
Vaccination
A total of 20 falcons were vaccinated with either a for-
malin inactivated WNV vaccine (Duvaxyn®) or a recom-
binant canarypox live WNV vaccine (RECOMBITEK®)
twice (groups 1 and 3) or three times (groups 2 and 4),
respectively. Prior to vaccination all falcons were seronega-
tive for WNV (ELISA, VNT) and USUV (VNT) specific
antibodies.
After vaccination no clinical side effects were observed
in groups 1, 2 (Duvaxyn®) and 4 (RECOMBITEK® three
times) at any time of the study. Falcons (5/5) in group 3
(RECOMBITEK® twice), however, showed an unexplained
interim reduction of body weight (of up to 20% and more).
Moreover, in this group local inflammations at the injection
sites (pustules, induration and slight swelling) were ob-
served in 3/5 birds (RECOMBITEK® two times), but oral
and cloacal shedding of recombinant canarypox viruses was
not observed, since swabs were negative for the ALVAC/
WNV-prM genome by nested PCR.
Two injections of Duvaxyn® (group 1) stimulated a
low antibody response by week 5 post vaccination
(ELISA positive results and VNT levels of 15 up to 80),
but these antibodies disappeared in 4/5 falcons until
week 8 (Figures 1A and B). However, three consecutive
injections of this inactivated vaccine (group 2) induced
a more robust antibody response and an abiding sero-
conversion in ELISA in all (5/5) falcons. Neutralizing
antibody titers in these birds reached 240 and lasted in
2/5 birds until the challenge date in week 8.
Antibody responses induced by the RECOMBITEK®
vaccine (groups 3 and 4) were generally lower than those
induced by the inactivated vaccine (group 1 and 2).Two canarypox vector vaccine applications induced
antibodies in 5/5 birds which disappeared in 3/5 falcons.
Maximum neutralizing titers were 15. Three vaccine appli-
cations raised ELISA detectable antibodies in 3/4 birds at
the end of the vaccination phase (8 wpv) and 1/4 falcons
developed a neutralizing antibody titre of 80.
Two falcons (F39, 8 wpv, inactivated group 2 and F46,
7 days post vaccination (dpv), recombinant group 4) died
suddenly for reasons most likely unrelated to the vaccin-
ation (severe visceral gout and severe intestinal endopara-
sitosis, respectively) and were therefore excluded from the
statistical analysis.
Challenge studies
Non-vaccinated control birds (NC - group 5)
Following WNV challenge all (8/8) non-vaccinated falcons
developed moderate to severe clinical signs including im-
paired general condition, crouched body postures, ruffled
feathers, apathy, inappetence, dehydration and a greenish
discoloured uric acid component of the excrements. All
birds lost body weight – in some animals up to 20% and
more. Neurological symptoms such as tilted head, ataxia,
seizures and recumbency were observed in two birds.
Overall four of the eight non-vaccinated WNV challenged
birds died or had to be euthanized for animal welfare rea-
sons on 3, 5, 8, and 14 dpi eventually. Mean duration of
clinical symptoms was 8.6 days (Additional file 1) with at
least moderate disease (clinical score of 2), in one bird
severe disease (clinical score of 3).
In these non-vaccinated control animals virus shed-
ding occurred from 3 to 14 dpi with an initial peak from
3 to 8 dpi (Figures 2A and B). Highest virus loads in oral
and cloacal swabs reached Ct values of 22.1 and 17.5, re-
spectively. Viral RNA was detected in the blood from 3 to
21 dpi with a peak during the first days (lowest Ct value
19.9) (Figures 3A and B). Virus loads in the organs of the
deceased or euthanized falcons were high (Table 1). Copy
numbers and Ct values of the organs of non-vaccinated
birds reached 402 895 cop/mg and 16.7, respectively. All
birds (except two which died early in the course of the ex-
periment after 5 and 8 dpi, respectively) seroconverted after
3 to 6 dpi (Figures 4A and B).
All falcons were necropsied either after death, euthanasia
or at the end of the observation period (21 dpi). One of the
eight animals died 3 days post challenge with severe acute
hemorrhagic enteritis and clear signs of septicaemia and
was therefore excluded from histopathological analysis.
However, molecular and immunohistochemical studies
showed that it was successfully infected (see below). The
seven remaining animals had pale and up to moderately
enlarged spleens and pale myocardial foci. Myocardial
petechiae were observed in one falcon which had died
after 5 dpi. Lesions seen histopathologically associated to
a WNV infection are mild to moderate non-suppurative
Figure 1 Antibodies in falcons detected by ELISA and micro-virus neutralization test (VNT) during vaccination period. Figure 1A shows
competition ELISA (ID Screen© WN competition ELISA, IDVet, Grabels, France) responses. Optical density at 450 nm is converted to signal/noise%
(S/N%) ratio (S/N% = ODsample/ODnegative control* 100), with values≤ 40% considered positive, > 40% and≤ 50% equivocal and > 50% negative.
The threshold for positive results is indicated as a solid red line. Figure 1B displays neutralization antibody responses for all groups. Data are
presented in a box-and-whisker plot, where the ends of the whiskers represent the minimum and maximum values, respectively. Outliers are
represented as points instead of whisker-ends. The box includes 50% of the values of each group and the line in the middle of each group
represents the median value of each group. The double immunization with inactivated vaccine (light blue) led to temporary seroconversion
whereas the triple vaccination (dark blue) was more efficient. The recombinant vaccine generally induced only a slight seroconversion. With two
shots of the recombinant vaccine (light green) low level and temporary seroconversion occurred, while three shots (dark green) provided a better
result measureable by ELISA but not by VNT.
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to moderate acute or subacute lymphohistiocytic necrotiz-
ing myocarditis (5/7). Non-suppurative necrotizing arteritis
was seen in the spleen of one bird only. All other findings,
affecting in particular spleen and liver are due to more
unspecific reactions. Detailed histopathological results are
shown in the supplemental data (Additional file 2).Figure 2 Oral and cloacal shedding of falcons during challenge. Cycle
groups are displayed. Data are presented in a box-and-whisker plot, where
values, respectively. Outliers are represented as points instead of whisker-en
the middle of each group represents the median value of each group. The am
group vaccinated three times with Duvaxyn® (dark blue, only amount reduce
but not in the group vaccinated twice with Duvaxyn® (light blue). In addition
Duration of cloacal shedding was not shortened in any of the groups.Immunohistochemical examination of the brains, hearts,
spleens and injection sites revealed differences between
the individual animals. WNV antigen was found in distinct
quantities in the fatally diseased animals (4/8), whereas only
very scant (2/8) or no (2/8) WNV antigen staining was
detected in challenge survivors. In order to demonstrate
a large WNV antigen deposition, IHC staining results ofthreshold values (Ct values) of oral (A) and cloacal (B) swabs for all
the ends of the whiskers represent the minimum and maximum
ds. The box includes 50% of the values of each group and the line in
ount and duration of oral shedding was significantly reduced in the
d) and in the groups vaccinated with Recombitek® (light and dark green),
, the amount of cloacal shedding was significantly reduced in all groups.
Figure 3 Viraemia detected by qRT-PCR and virus titration. Cycle threshold values (Ct values) of whole blood for all groups during the
challenge period are displayed in Figure 3A. Results of blood titration for all groups during the challenge period are given in Figure 3B in log10
tissue culture infection dose 50 per mL (TCID50/mL) whole blood. Data are presented in a box-and-whisker plot, where the ends of the whiskers
represent the minimum and maximum values, respectively. Outliers are represented as points instead of whisker-ends. The box includes 50% of
the values of each group and the line in the middle of each group represents the median value of each group. The level of viraemia measured in
Ct values was significantly lower in all vaccinated groups than in the control group (yellow). In contrast, duration of viraemia was only shortened
significantly in the group vaccinated three times with Recombitek® (dark green).
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ment [12] are reported here for comparison. Figure 5A-C
shows the immunohistochemical reaction pattern in
different tissues, a detailed description can be found in
the supplemental data (Additional file 2).
Environmental control bird (group 6)
The non-vaccinated, non-infected control bird (F63) did
not develop any clinical signs during the challenge period,Figure 4 Antibodies detected by ELISA and micro-virus neutralization
all groups detected by the ID Screen© WN competition ELISA (IDVet, Grabe
at 450 nm is converted to signal/noise% (S/N%) ratio (S/N% = ODsample/OD
and≤ 50% equivocal and > 50% negative. The threshold for positive results
groups determined by VNT against homologous challenge virus (neutraliza
presented in a box-and-whisker plot, where the ends of the whiskers repre
represented as points instead of whisker-ends. The box includes 50% of th
represents the median value of each group. Seroconversion occurred at 3and no WNV RNA and no WNV-reactive antibodies were
detected in swab, blood and organ samples.
Inactivated vaccine - two dose regimen (Duxaxyn® - group 1)
Falcons immunized twice with the inactivated vaccine suf-
fered from clinical infection for 7.6 days on average and one
falcon died after 9 dpi. Four out of five birds showed signs
of moderate illness (clinical score of 2; Additional file 1)
over several days and one bird developed only mild diseasetest (VNT) during challenge in falcons. In Figure 4A antibodies of
ls, France) during the challenge period are displayed. Optical density
negative control * 100), with values≤ 40% considered positive, > 40%
is indicated as a solid red line. In Figure 4B antibody titers of all
tion titer) during the challenge period are displayed. Data are
sent the minimum and maximum values, respectively. Outliers are
e values of each group and the line in the middle of each group
to 6 dpi.
Figure 5 WNV antigen dectection by immunohistochemistry in different tissues of falcons after virus challenge. A: Brain/Telencephalon
(region lateral of the lateral ventricle) of a challenged falcon (F6) included in a previously published study [12] at day 10 post infection. B: Spleen
of a bird at day 8 post infection without vaccination (F51). Antigen was detected in necrotic material of follicle arteries. C: Myocard of a falcon
vaccinated twice with the inactivated vaccine (F17, necropsied at day 9 post infection). Antigen staining in cardiocytes (arrows). All results were
obtained using the monoclonal antibody 15R4 (kindly provided by Petra Emmerich, Bernhard-Nocht Institute, Hamburg, Germany).
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cantly lower (p value 0.01677, Additional file 3) than those
of the non-vaccinated falcons. Vaccinated falcons shed
WNV orally (3 to 8 dpi/lowest Ct value of 25.7) and cloa-
cally (3 to 12 dpi/lowest Ct value of 24.8) for the same time
period as the non-vaccinated animals (p values 0.1013 and
0.1663). However, the extent of cloacal shedding (p value of
0.0001274) but not of oral shedding (p value 0.06382) was
significantly reduced in comparison to group 5.
All birds in this group developed viraemia (from 3 to
6 dpi). While the duration of viraemia was not significantly
reduced (compared to group 5; p value 0.1566), viraemia
levels were significantly lower (lowest Ct value of 23.5,
p value 4.468e-05). Copy numbers in brain, spleen, kidney
and heart at 21 dpi were similar to those in non-vaccinated
falcons (p values > 0.1286). The one falcon which died (F17)
had very high viral loads, especially in the heart, with a Ct
value of 11.7 (details Table 1). The remaining birds showed
evidence of viral infection in organs; especially in the kidney
(Ct values to 27.9). Nonetheless 1/5 birds (F14) was
completely negative in all organs.
Organs of all surviving birds were virus negative in cell
culture (kidney, brain and heart of F17 were positive).Seroconversion was observed in 2 birds by 3 dpi and in
all birds by 6 dpi as determined by ELISA and VNT. Max-
imum VNT titers ranged from 640 to 24 000 eventually.
One bird (1/5, F15) displayed only mild phlebitis at
the vacciniation site. All other birds (4/5) showed acute,
nonsuppurative encephalitis of varying degress, in one case
(F16) with involvement of the meninges. Additionally, acute
to subacute necrotizing myocardial lesions of varying
degrees (4/5) and mycordial petechiae (1/5) were present.
The pale and enlarged spleen of all falcons showed
nonspecific signs such as severe lymphoid depletion
with marked lymphocytolysis in the few remaining fol-
licles (3/5) and infiltration of bloated foamy macro-
phages (5/5). In immunohistochemistry 2/5 birds had
antigen in different organs. In the fatally diseased animal
(F17) antigen was detectable in all examined organs, espe-
cially in the heart (positive reactions in > 75% of the myo-
cardium, Figure 5C).
Inactivated vaccine - three dose regimen (Duvaxyn® - group 2)
Following three immunizations falcons developed only mild
disease (maximum clinical score of 1, i.e. significantly re-
duced clinical scores compared to non-vaccinated controls;
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oral and cloacal shedding and viraemia still occurred
in the animals of this group, albeit only at very low
levels (oral shedding on days 3 to 8, lowest Ct value
29.6/cloacal shedding on days 3 to 10, lowest Ct value
29.1/viraemia days 3 up to 6, lowest Ct value 28.1).
The amount of oral and cloacal shedding and viraemia
was significantly reduced compared to non-vaccinated
birds (p values of 1.269e-08, 2.006e-06 and 3.43e-08).
Duration of oral and cloacal shedding and viraemia was not
shortened (p values > 0.06). No virus was detectable in any
organ at the end of the study and viral RNA was detectable
in low amounts in 3/4 animals (Ct values > 35.0) in single
organs (statistically significant difference to control group
for brain, kidney, heart compared to negative control group
5; p values 0.0128, 0.0128, 0.02953; for spleen 0.1125).
All 4/4 birds elicited neutralizing antibody titers with
peak titers ranging from 5120 to 10240.
One bird (F41) developed lymphocytolysis of locally
aggregated follicles at the vaccination site. However
histopathological findings in some of the birds were
typical for WNV infections. F38 displayed acute non-
suppurative encephalitis and necrotizing myocarditis.
F40 had a weak encephalitis combined with local lym-
phohisticytic inflammation at the vaccination site and
F37 showed necrotizing arteriitis in connective tissues
(skin, parenchymas) and in liver which was associated
with acute necrosis of hepatocytes and mixed cell infil-
tration. Additionally, extensive PALS necrosis with fi-
brin deposition and involvement of giant cells was seen
in the spleen. All bird tissues which were examined by
IHC at 21 dpi gave negative results.
Recombinant canarypox vector vaccine two dose regimen
(Recombitek® - group 3)
Falcons vaccinated twice with the recombinant canarypox
vector vaccine developed moderate disease (maximum
clinical score of 2), including one bird showing only
mild disease (clinical score of 1; mean duration 7.8 days;
in comparison to non-vaccinated group p value 0.005155).
Compared to the non-vaccinated controls virus shedding
by the oral and cloacal route was significantly reduced
(max. Ct values of 28.4 and 24.8 respectively; p values
9.710e-07, 2.385e-05) and oral shedding ceased earlier
(12 dpi, p value 0.03158; cloacal shedding 14 dpi, p value
0.1442). Indeed 3/5 animals showed only borderline qRT-
PCR results for oral shedding (Ct values > 35.0). Viraemia
was detected in all birds at significantly lower levels (lowest
Ct level 26.8, p value 1.025e-07), but lasted as long as in the
non-vaccinated animals (p value 0.07688).
Single organs of 2/5 birds in this group were qRT-PCR
positive, e.g. one brain (F21) with a Ct value of 26.9 being
the only organ with a positive titer in cell culture. Viral
loads in spleen, kidney and heart were lower than in thecontrol group (p values 0.02228, 0.01063, 0.008443; for
brain 0.0561).
At 6 dpi all birds in group 3 seroconverted (maximum
titers from 9360 up to 20480). All falcons displayed ex-
tensive granulomatous myositis at the vaccination site.
Only mild histopathological findings associated with
WNV infection were seen in 4/5 birds and included
nonsuppurative (meningo)encephalitis (3/5) and subacute
necrotizing myocarditis (3/5). Nonspecific signs in spleen
and liver, as described above for the control falcons, were
seen in all animals.
Weak WNV antigen staining was found by IHC in 2/5
birds (in spleen and in heart and diencephalon respectively).
Recombinant canarypox vector vaccine three dose regimen
(Recombitek® - group 4)
Three vaccinations with the recombinant vaccine led
to very mild WNV associated disease in 4/4 animals
(maximum clinical score of 1; compared to the non-
vaccinated birds statistically significant with a p value
0.00418, mean duration 3.75 days).
Oral shedding was observed in only 1/4 birds (6 dpi, Ct
value 34.4) and cloacal shedding in 2/4 birds (3 to 21 dpi
with peak at 3 to 6 dpi; lowest Ct value 31.3), however 1/4
birds showed borderline qRT-PCR results (Ct values > 35).
The amount of oral and cloacal shedding and duration
of oral shedding were significantly reduced compared to
non-vaccinated group 5 (p values 1.040e-11, 1.187e-06,
0.006011; for duration of cloacal shedding 0.1139).
In 2/4 birds viraemia was detected on 3 to 6 dpi
(lowest Ct values of 33.7; level and duration significantly
reduced compared to group 5 with p values of 1.723e-09
and 0.02339).
By qRT-PCR a low level of WNV RNA (Ct > 33.0) was
found in one falcon (p-values of brain, kidney and heart
0.01377, 0.0128, 0.02953; for spleen 0.1125; compari-
son data of non-vaccinated birds), but virus could not
be re-isolated by cell culture from any of the organs.
All birds seroconverted at 6 dpi reaching maximum
neutralization titers from 960 to 2560.
At the vaccination sites extensive granulomatous
(4/5 birds) and pyogranulomatous (1/5 birds) myositis
was detectable in all animals. 2/5 birds showed moderate
(meningo-)encephalitis as well as myocardial alterations
such as acute hemorrhage and necrotizing myocarditis. In
addition F44 showed mild lymphohistiocytic hepatitis,
pancreatitis and neuritis. The spleen was inconspicuous in
gross examination (3/4 birds), but lymphoid depletion and
lymphocytolysis was seen in two animals. By IHC one bird
(F44) was slightly positive in heart.
Discussion
WNV infections in large falcons can be fatal [12]. So far,
there is no WNV vaccine approved for use in any bird
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avian species following the application of commercially
available vaccines are available. The aim of the present
study was therefore to evaluate the efficacy and safety of
two WNV vaccines in large falcons.
The inactivated virus vaccine used in the present study
was used in red-tailed hawk before, where it failed to
stimulate a detectable antibody response using a two
shot regimen and reduced vaccine doses (20% of the full
dose) [27]. In another study a three shot full dose regi-
men led to a detectable seroconversion (NT titers of 10)
in 58.3% of birds of prey (including falcons) and cor-
vids, but no challenge studies were conducted [26]. In
the present study a higher seroconversion rate and
higher maximum antibody titers were achieved in falcons
using a similar vaccination scheme. The fact that sampling
was conducted at different time points after vaccination
limits comparability of both studies. However, the present
study is the first one that determines the true efficacy
of the vaccine by subsequent WNV challenge studies
in a raptor species.
The immunogenicity of the canarypox vector vaccine
has been studied in Western scrub-jay recently, but failed
to stimulate antibody responses after single vaccination,
and pathological alterations typical for WNV infections and
reduced viraemia were observed after WNV NY99 chal-
lenge [20]. The absence of antibody responses at two and
four wpv in the scrub-jays corresponds to findings in the
present study in falcons. In these scrub-jays, vaccine appli-
cation induced massive necrotic lesions at the application
sites (i.e. pectoral muscles) [20]. These findings correspond
to results in the present study. In falcons the inactivated
virus vaccine was tolerated well (mild non-specific inflam-
matory response at the injection site in single animals), but
the canarypox-based vaccine caused a massive local inflam-
mation in most animals.
Environmental safety is an important issue for this
genetically engineered vaccine. As the canarypox vector
virus was shed neither orally nor via feces by any of the
vaccinated falcons, this concern seemed to be unjusti-
fied. However, the host species restriction might not be
as tight as expected, since local amplification may have
occurred at the injection site. Previous studies have
shown that this vector (ALVAC) does not replicate in
mammals [37], but is able to replicate in chicken cells
in vitro [37].
Two injections of the inactivated vaccine provided only
insufficient protection. Animals were in poor clinical con-
dition post challenge and one bird died. Although the
amount of cloacal shedding was reduced significantly, the
amount of oral shedding and the duration of shedding
were not reduced. Viraemia was present in falcons of this
group, even though levels were generally lower than those
observed in non-vaccinated control falcons. The thresholdfor infectiveness to Culex pipiens mosquitoes is considered
to be 105 pfu/mL serum [7] which was still reached using
the two shot regimen. Therefore birds could have been in-
fectious for mosquitos.
In comparison, triple immunization with the inactivated
vaccine led to much lower clinical scores and virus
shedding and also to viraemia levels well below mosquito
infectiousness.
In terms of protection against WNV challenge, the live
recombinant canarypox based vector vaccine may be
regarded as superior to the inactivated vaccine, which is
supported by the fact that besides antibody production
live vaccines also stimulate cellular immune responses
[37]. In the present study two vaccinations with the re-
combinant vaccine did not prevent clinical disease. Viral
shedding and viraemia still occurred, although at a lower
level than in non-vaccinated birds, effectively blocking
transmission to mosquitoes.
Triple vaccination with the canarypox-based vaccine
also failed to completely protect the falcons. However,
clinical symptoms were reduced sufficiently and shedding
of WN-viral RNA was decreased and in some birds com-
pletely eliminated. Additionally, this vaccination schedule
provided sterile immunity in two birds and low levels of
viral RNA detection among blood and organs.
Independently of the vaccination scheme, specific patho-
logical findings for WNV were found in nearly all animals,
such as nonsuppurative (meningo)encephalitis and necro-
tizing myocarditis of varying degrees [12]. Given the differ-
ences in the course of the disease in the single animals,
there are also individual/multifactorial factors in addition to
the vaccination which had an impact on how the animals
overcame WNV challenge. As decribed by others [38-40]
lymphohistiocytic inflammations were seen in different
parenchymas (liver, kidney, pancreas, peripheral nerves),
however, in single animals only. Therefore these inflam-
mations might not be associated with WNV infection
directly. Alterations of the spleen were most probably
due to nonspecific reactions associated with viral infec-
tions (i.e. severe lymphoid depletion and lymphocytoly-
sis of remaining follicles, PALS necrosis) or due to the
outcome of the disease, such as the detection of foamy
bloated macrophages which are indicative for an altered
fat metabolism [41].
Only low amounts of viral antigen were detected by
IHC in most animals, most probably due to the fact that
most falcons survived the challenge and were necropsied
only at the end of the study period. In contrast, distinct
IHC reaction patterns were found in animals which died/
had to be euthanized due to severe clinical signs. This cor-
responds to a maximal viral load of the different paren-
chymas. These results suggest that the time frame for the
immunohistochemical detection of WNV antigen might be
finite and closely associated with severe clinical disease.
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tection when administered three times. Therefore this
scheme is recommended for falcons, if feasible. Duvaxyn
can be administered safely. Our data indicate that the
canarypox vectored vaccine provides a better protection
against viraemia and shedding, but safety concerns and
adverse reactions may limit its use. In both cases viremia
levels may be below the transmissibility limits for arthro-
pods which may be considered as an additional indirect
protection approach. Further studies are needed to de-
termine the longevity of the protective effect of the
vaccination and a possible cross-protection of falcons
to WNV lineage 2.
Additional files
Additional file 1: Clinical scores of falcons during challenge. Clinical
score ranging from 0 to 4 is illustrated using a colour code with clinical
score of 0 in white = healthy, clinical score of 1 in yellow = mildly
affected, clinical score of 2 in orange = moderately affected, clinical score
of 3 in red = severely affected and clinical score of 4 in dark purple = death.
Grey fields indicate that the bird was taken out of the experiment at 19 or
20 days post infection (dpi) regularly. All groups presented less clinical
disease than the unvaccinated control group following infection with WNV.
These differences were statistically significant.
Additional file 2: Pathological (HE) and immunohistochemical (IHC)
results for the falcons. High IHC scores were only detected in falcons
that died suddenly or had to be euthanized following infection with
WNV lineage 1 NY’99.
Additional file 3: Results of statistical analyses. Results of statistical
analyses for the variables clinical scores, oral and cloacal shedding,
viremia and viral load of brain, spleen, kidney and heart are shown. For
each variable the results of each group (groups 1, 2, 3 and 4) were
compared to the results of group 5. P values below α-levels of 0.05 were
considered statistically significant.
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